(NewsVisual, powered by IntellectSpace) -- Genentech Inc (NYSE: DNA) was in for a surprise when partner Roch Holdings AG made it's $44 billion takeover offer. The move could significantly change the way the two do business from here on out.

Roche already controls 56% of the biotechnology company, though Genetentech employees expressed concern about the impact that a full takeover could have on the company's corporate culture. The fate of the remaining 44% of Genentech is still unknown as executives maintained their silence through Monday (see article from The Wall Street Journal).

Despite resistance from employees, the fact that Genentech and Roche are already so closely tied could mean that an agreement is right around the corner. Having already been Genentech's closest partner, Roche likely has all the necessary insight into what needs to happen to secure a deal.

Genentech may not warmly embrace a deal, but the connections, as illustrated on this IntellectSpace Knowledge Map, could go far in facilitating the transition if Roche successfully pursues full ownership of the company.